Drug Profile


Alternative Names: ALP; ET 18 O CH3; ET 18 OME; NSC 324

Latest Information Update: 06 Apr 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Thorax Hospital
  • Developer Calbiochem; Thorax Hospital
  • Class Antineoplastics; Immunotherapies; Phospholipids
  • Mechanism of Action Angiogenesis inhibitors; Phosphocholine acyltransferase inhibitors; Phospholipase C inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 06 Apr 2004 Discontinued - Phase-II for Cancer in Germany (unspecified route)
  • 06 Apr 2004 Discontinued - Preclinical for Cancer in France (unspecified route)
  • 06 Apr 2004 Discontinued - Preclinical for Cancer in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top